EMEA-002326-PIP04-20-M01
EMEA-002326-PIP04-20-M01
EMEA-002326-PIP04-20-M01
Opinion/decision on a Paediatric investigation plan (PIP): Kaftrio, elexacaftor,tezacaftor,ivacaftor, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Other, PIP number: P/0392/2023
EMEA-002310-PIP01-17-M01
Opinion/decision on a Paediatric investigation plan (PIP): Ultomiris, ravulizumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Uro-nephrology, PIP number: P/0353/2023
Opinion/decision on a Paediatric investigation plan (PIP): Tavneos, Avacopan, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Immunology-Rheumatology-Transplantation, PIP number: P/0352/2023
Opinion/decision on a Paediatric investigation plan (PIP): Ultomiris, ravulizumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Uro-nephrology, PIP number: P/0379/2023
Opinion/decision on a Paediatric investigation plan (PIP): Ajovy, fremanezumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Neurology, PIP number: P/0378/2023
EMEA-002883-PIP02-22
Opinion/decision on a Paediatric investigation plan (PIP): Verzenios, abemaciclib, decision type: W: decision granting a waiver in all age groups for all conditions or indications, therapeutic area: Oncology, PIP number: P/0367/2023
Opinion/decision on a Paediatric investigation plan (PIP): Padcev, Enfortumab vedotin, decision type: W: decision granting a waiver in all age groups for all conditions or indications, therapeutic area: Oncology, PIP number: P/0385/2023